|1.||Hofmann, Francesco: 6 articles (06/2012 - 05/2005)|
|2.||García-Echeverría, Carlos: 4 articles (06/2012 - 05/2005)|
|3.||Scotlandi, Katia: 3 articles (09/2012 - 05/2005)|
|4.||Picci, Piero: 3 articles (09/2012 - 05/2005)|
|5.||Minami, Hironobu: 2 articles (04/2013 - 09/2009)|
|6.||Mukohara, Toru: 2 articles (04/2013 - 09/2009)|
|7.||Modjtahedi, Helmout: 2 articles (01/2013 - 11/2008)|
|8.||Manara, Maria Cristina: 2 articles (09/2012 - 05/2005)|
|9.||Oenema, Tjitske: 2 articles (06/2011 - 01/2010)|
|10.||de Vries, Elisabeth G E: 2 articles (06/2011 - 01/2010)|
08/15/2010 - "The ability of NVP-AEW541 to block this circuit could be beneficial in suppressing the growth and angiogenic potential of hypoxic glial tumors."
06/01/2012 - "We have assessed the efficacy of NVP-AEW541 in repressing tumor growth and tumor progression in the Rip1Tag2 transgenic mouse model of pancreatic β-cell carcinogenesis. "
06/01/2012 - "Unexpectedly, treatment of Rip1Tag2 mice with NVP-AEW541 in prevention and intervention trials neither did affect tumor growth nor tumor cell proliferation and apoptosis. "
06/01/2012 - "In addition, we have tested NVP-AEW541 in Rip1Tag2;RipIGF1R double-transgenic mice which show accelerated tumor growth and increased tumor malignancy compared with Rip1Tag2 single-transgenic mice. "
06/01/2008 - "Moreover, the combination of NVP-AEW541 and chemotherapy was highly effective against tumors in mice. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2013 - "In this study, we investigated the effect of simultaneous targeting of IGF-IR and HER (erbB) family, with NVP-AEW541 and afatinib, on proliferation of pancreatic cancer cells. "
01/01/2013 - "Interestingly, of the various combinations examined, treatment with a combination of NVP-AEW541 and afatinib was superior in inducing synergistic growth inhibition of the majority of pancreatic cancer cells. "
01/01/2013 - "All pancreatic cancer cell lines were found to be IGF-IR positive and NVP-AEW541 treatment inhibited the growth of the pancreatic cancer cell lines with IC50 values ranging from 342 nM (FA6) to 2.73 μM (PT45). "
01/01/2013 - "Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells."
07/01/2008 - "Human pancreatic cancer cells and endothelial cells were employed, and effects of NVP-AEW541 on signalling pathways investigated by Western blotting. "
02/01/2006 - "The anti-neoplastic activity of NVP-AEW541 in ovarian cancer was observed at concentrations higher than those previously reported for multiple myeloma, suggesting the possibility that a portion of the observed anti-neoplastic activity could involve targets other than the IGF-IR. "
04/01/2009 - "Taken together, we show that the combined inhibition of IGF-1R and mTOR by combining NVP-AEW541 and Rad001 is highly effective in multiple myeloma and might represent a potential new treatment strategy."
05/01/2008 - "The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells."
|4.||Esophageal Neoplasms (Esophageal Cancer)
07/01/2012 - "Stimulation of RAS-MAPK pathway is associated with resistance to NVP-AEW541 in esophageal cancer. "
07/01/2012 - "Active RAS was not reduced by NVP-AEW541 in esophageal cancer cells TE-1, suggesting that insensitivity of esophageal cancer to NVP-AEW541 is due to the maintained RAS-MAPK activity, which did not arise from RAS mutation. "
07/01/2012 - "More than 2 μmol/l of NVP-AEW541 was required to effectively inhibit the proliferation of esophageal cancer. "
07/01/2012 - "Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity."
07/01/2012 - "Combining NVP-AEW541 with inhibitors/antibodies against RAS-MAPK signaling molecules might be more effective for use against esophageal cancer."
|5.||Breast Neoplasms (Breast Cancer)
04/01/2013 - "We developed an acquired resistant model by continuously exposing MCF-7 breast cancer cells to NVP-AEW541 (MCF-7-NR). "
11/01/2008 - "Combination studies with several drugs used in the breast cancer clinic showed that NVP-AEW541 synergistically increased the action of trastuzumab. "
04/01/2012 - "We studied responses to IGF1R tyrosine kinase inhibitor NVP-AEW541 combined with conventional systemic drugs in breast cancer cell lines of different clinical subtype. "
09/08/2009 - "Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression."
11/01/2008 - "Our results show the anti-breast cancer action of NVP-AEW541 and support the clinical development of anti-IGF-IR agents, especially in combination with trastuzumab."
|7.||IGF Type 1 Receptor (IGF 1 Receptor)
|8.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Transplantation (Transplant Recipients)